At the end of 2019, Meducom was invited by an international biotechnology company specialised in diseases of the central nervous system with high unmet medical needs for a competitive pitch to provide medical and scientific communication support for the development of medical information materials for a new medicine for a rapidly progressing form of an auto-immune disease. We are extremely pleased that Meducom was selected as agency of choice based on our broad track record in the field of neurology and neuropsychiatry as well as our in-depth knowledge of auto-immune neurological diseases and their underlying pathologies. Because of our longstanding experience in developing tailor-made, top-quality medical communication and education programmes for many different audiences in a large variety of disease areas and our competitive rates, we were standing out and therefore selected as their preferred supplier.